Physician profile
Trevor E Cox
NPI 1265842231
$8,795.02
in general payments reported to CMS, 2019-2025
36 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $1,154 · 2021: $1,415 · 2022: $1,193 · 2023: $1,696 · 2024: $1,480 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,537 · Education: $38.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,536.96 |
| Education | $38.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,308.34 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $968.75 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $932.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $878.98 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $802.18 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $561.53 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $477.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Kowa Pharmaceuticals America, INC. | $467.29 | 2019-2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $335.44 | 2019-2025 | |
| Pfizer INC. | $329.51 | 2019-2024 | |
| Lilly USA, LLC | $309.40 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $199.49 | 2019-2023 | Belsomra, Steglatro |
| Allergan, INC. | $187.82 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $117.53 | 2021-2025 | Contrave, Nexlizet, Nexletol |
| Biohaven Pharmaceuticals, INC. | $114.13 | 2020-2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.